Вход на сайт

Просмотр новости

Найдите то, что Вас интересует

STAT+: A ‘historic’ FDA clearance raises the question: Is the LLM an interface or the decision-maker?

Дата публикации: 02-07-2026 08:30:00

The newly cleared device is based around an app that helps a patient manage their diabetes using a treatment plan defined by their doctor.

Основное содержимое страницы с новостью.

UpDoc’s CEO wouldn’t say whether generative AI in the company’s diabetes app makes treatment decisions
Adobe

Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer wearables. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13.

Digital health company UpDoc prompted a flurry of discussion when it announced in late June that its app for people with diabetes had received the first Food and Drug Administration clearance for medical software using “patient-facing large language models.” 

Founded in 2023, UpDoc received clearance for the device in December and is just now publicly revealing its plans to use the technology as part of a care model that helps health systems manage patients outside the clinic with the help of AI.

The newly cleared device is based around an app that helps a patient manage their diabetes using a treatment plan defined by their doctor. It’s regulated in the same product category with drug dose calculators that take inputs like blood glucose levels and return insulin dosing recommendations. A big part of what makes UpDoc’s app different is a chatbot-like interface based on large language models, or LLMs. Patients can input data using voice and text, and the device responds with treatment instructions. The technology also communicates back to a doctor’s electronic medical record software to keep them in the loop.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. Health Tech Correspondent

    Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer wearables. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Glooko предоставит доступ к удаленному контролю за пациентами с сахарным диабетом0020-03-2020
2STAT+: A former AI regulator, now in industry, says biopharma is reading FDA’s guidance wrong0502-07-2026
3STAT+: U.S. judge blocks Colorado’s first-of-its-kind price cap on an Amgen drug0502-07-2026
4STAT+: Lawmakers urge HHS to force Eli Lilly to provide 340B drug discounts to hospitals0502-07-2026
5STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more0502-07-2026
6STAT+: Elevance sues government over $115 million tied to Medicare Advantage star ratings0502-07-2026
7STAT+: Roche drug sets new standard for KRAS-driven lung cancer 5702-07-2026
8STAT+: What does DeGette’s loss mean for pharma?0502-07-2026
9Решение Ростеха для "медицинских помощников" включили в реестр отечественного ПО0025-03-2025
10В саратовских медучреждениях внедрят нейросеть для обзвона пациентов0022-02-2025

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: www.statnews.com.